Scholar Rock (SRRK)
NASDAQ: SRRK
· Real-Time Price · USD
34.27
-5.19 (-13.15%)
At close: Oct 13, 2025, 3:59 PM
35.30
2.99%
After-hours: Oct 13, 2025, 04:48 PM EDT
-13.15% (1D)
Bid | 33.21 |
Market Cap | 3.29B |
Revenue (ttm) | n/a |
Net Income (ttm) | -315.69M |
EPS (ttm) | -2.92 |
PE Ratio (ttm) | -11.74 |
Forward PE | -15.83 |
Analyst | Buy |
Dividends | n/a |
Ask | 36.8 |
Volume | 11,204,373 |
Avg. Volume (20D) | 2,480,428.5 |
Open | 32.87 |
Previous Close | 39.46 |
Day's Range | 29.00 - 35.42 |
52-Week Range | 22.71 - 46.98 |
Beta | 0.43 |
Ex-Dividend Date | n/a |
About SRRK
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SRRK
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for SRRK stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsScholar Rock is scheduled to release its earnings on
Nov 11, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 hours ago
Scholar Rock shares are trading lower after the co...
Unlock content with
Pro Subscription
2 weeks ago
+3.59%
SRRK stock has given up its prior loss. Scholar Rock Holding shares were trading lower after the company announced that the FDA issued a Complete Response Letter for the apitegromab Biologics License Application for the treatment of patients with spinal muscular atrophy.

2 weeks ago · seekingalpha.com
Scholar Rock: Despite CRL, This Is A Strong Buy With Apitegromab ExpansionsScholar Rock Holding Corporation remains a Strong Buy despite a recent FDA Complete Response Letter for apitegromab in spinal muscular atrophy. The CRL was due to manufacturing site issues with Catale...